吴一诺

吴一诺

教授

研究领域：靶向磷酸二酯酶的首创药物设计与发现

办公电话： 020-39943062

联系邮箱： wyinuo3@mail.sysu.edu.cn

简单介绍

吴一诺 博士，教授，博士生导师，广东省“珠江学者”青年学者。主要从事"靶向磷酸二酯酶的首创药物设计与发现"。目前已在 J. Med.Chem, Acta Pharma. Sin. B. Org. Lett., Chem.Commun.等国际权威杂志发表高水平收录论文60余篇。共主持国家自然科学基金等项目9项，并作为课题骨干参与国家科技部重点研发计划。

教育经历

2006/09 - 2011/06，中山大学，药学院，药物化学，博士

2002/09 - 2006/06，中山大学，化学与化学工程学院，应用化学系，学士

工作经历

2026/01-至今        ，中山大学，药学院，教授

2018/04- 2026/01，中山大学，药学院，副教授

2013/07 - 2018/04，中山大学，药学院，讲师

2011/07 - 2013/06，香港理工大学，应用生物与化学科技系，博士后

教学情况

中山大学第十一届教师教学竞赛理科组特等奖

《现代分析技术与应用》

《医学基础化学》

《大学化学实验》

科研项目

1. 国家自然科学基金面上项目，抗血管性痴呆嘧啶酮类PDE1选择性抑制剂的结构优化与作用机制研究，项目编号：22377155；2024.01 - 2027.12; 50万元

2. 国家自然科学基金面上项目，选择性磷酸二酯酶9型抑制剂的成药性优化及抗肺纤维化作用研究，项目编号：21977127；2020.01 - 2023.12; 66万元

3. 国家自然科学基金青年项目，钯催化下甲苯类酰化试剂参与的邻位和间位C-H酰基化反应，项目编号：21402243；2015.01 - 2017.12; 25万元

4. 广东省自然科学基金面上项目，高选择性磷酸二酯酶9型抑制剂的设计、成药性优化及其抗血管性痴呆作用研究，项目编号：2019A1515011883；2019.01 - 2022.12; 10万元

5. 广州市科技计划项目珠江科技新星专题，新型萘内酰亚胺类磷酸二酯酶二型抑制剂的合理化设计、合成及其抗阿尔茨海默症药效研究，2018.01 - 2020.12；30万元。

6. 中山大学青年教师培育基金，C-H键磷酯方法高效构建苯（杂）环类有机磷化合物新型方法研究，项目编号：13ykpy10；2013.11 - 2016.12；15万元。

7. 国家重点研发计划，课题骨干，基于E 级高性能计算生物医药应用软件系统研制及应用。课题四：癌症、糖尿病与感染性疾病新药研究与软件应用验证, 课题编号：2017YFB0202604; 2017.07 - 2020.12; 749万元。

论著专利

  1. Jiang, M. Y.; Zhou, Q.; Tian, X. L.; Zhang, J. N.; Xue, Z. H.; Zhang, C.; Luo, H. B.; Wu, Yinuo* Discovery of Selective PDE1 Inhibitors Alleviating Pulmonary Fibrosis by the Regulation of TGF-beta/Smads and MAPK Pathways. Journal of medicinal chemistry 2025, 68 (17), 18423–18435. 
  2. Zhao, Z. J.; Jiang, M. Y.; Huang, M. X.; Yang, Y. Y.; Feng, L. L.; Zhang, C.; Huang, Y. Y.; Luo, H. B.; Wu, Yinuo* Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis. Journal of medicinal chemistry 2024, 67 (10), 8309–8322. 
  3.  Li, Z.; Jiang, M.-Y.; Liu, R.; Wang, Q.; Zhou, Q.; Huang, Y.-Y.; Wu, Yinuo*; Zhan, C.-G.; Luo, H.-B. Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach. Acta Pharmaceutica Sinica B 2024. DOI: 10.1016/j.apsb.2024.06.021.
  4. Jiang, M. Y.; Zhang, C.; Huang, Q. H.; Feng, L. L.; Yang, Y. Y.; Zhou, Q.; Luo, H. B.; Wu, Yinuo*. Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket. Journal of medicinal chemistry 2024, 67 (22), 20203–20213. 

  5. Zhou, Q. #; Le, M.#; Yang, Y.; Wang W.; Huang, Y.; Wang, Q.; Tian, Y.; Jiang, M.; Rao Y.*; Luo, H.-B.*; Wu, Yinuo*, Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis.Acta Pharmaceutica Sinica B.2023，13, 1180-1191.

  6. Zhang, B. #;  Yang, Y.#; Zhao, Z-J.#; Wang W.; Huang, Y.; Wang, Q.; Tian, Y.; Jiang, M.; Wang, Q.*; Luo, H.-B.*; Wu, Yinuo*, Identification of novel quinolin-2(1H)-ones as phosphodiesterase 1 inhibitors for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry.2023, 66, 12468.

  7. Huang, M. X. #; Tian, Y. J. #; Han, C.; Liu, R. D.; Xie, X.; Yuan, Y.; Yang, Y. Y.; Li, Z.; Chen, J.;* Luo, H. B.*; Wu, Yinuo*. Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.Journal of Medicinal Chemistry.2022, 65, 8444-8455.

  8. Wu, X.-N.#; Qian, Z. #; Huang, Y.-D.; Xie X; Li Z; Wu, Yinuo*; Luo, H.-B.*, Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia. Acta Pharm. Sin. B 2022, 12, 3103-3112. 

  9. Wu Y, Wang Q, Jiang MY, Huang YY, Zhu Z, Han C, et al. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. Journal of Medicinal Chemistry.2021;64, 9537-49.

  10. Wu Y#, Li Z, Yun-Song Zhao, et al. Therapeutic targets and potential agents for the treatment of COVID-19. Med Res Rev,2021, 41, 1775-1797. 

  11. Wu, Y.;  Tian, Y. J.;  Le, M. L.;  Zhang, S. R.;  Zhang, C.;  Huang, M. X.;  Jiang, M. Y.;  Zhang, B.; Luo, H. B., Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry.2020,63, 7867-7879. 

  12. Wu, Yinuo#; Zhou, Q.#; Zhang, T.#; Li, Z.; Chen, Y. P.; Zhang, P.; Yu, Y. F.; Geng, H.; Tian, Y. J.; Zhang, C.; Wang, Y.; Chen, J. W.*; Chen, Y.*; Luo, H. B.*, Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. Journal of Medicinal Chemistry.2019, 62, 4218-4224. 

  13. Huang, Y. Y.; Yu, Y. F.; Zhang, C.; Chen, Y.; Zhou, Q.; Li, Z.; Zhou, S.; Li, Z.; Guo, L.; Wu, D. *; Wu, Yinuo;*; Luo, H. B. *, Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. Journal of Medicinal Chemistry.2019, 62, 3707-3721.

  14. Wu, Yinuo; Li, Z.; Huang, Y.-Y.; Wu, D.; Luo, H.-B. *, Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease. Journal of Medicinal Chemistry.2018, 61, 5467-5483.

  15. Wu, X. N.; Huang, Y. D.; Li, J.; Yu, Y.-F.;Zhou, Q.; Zhang, C.; Wu, Yinuo*and Luo, H.-B.* Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. Acta Pharmaceutica Sinica B.2018, 8, 615-628.